Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.

Gynecologic oncology - 1 Jan 2012

Meiser B, Gleeson M, Kasparian N, Barlow-Stewart K, Ryan M, Watts K, Menon D, Mitchell G, Tucker K

Abstract excerpt

OBJECTIVE: There is growing evidence that the BRCA mutation status of women newly diagnosed with ovarian cancer may be used to make treatment recommendations in the future. This qualitative study aimed to assess women's attitudes and experiences toward treatment-focused genetic testing (TFGT). METHODS: Women (N=22) with ovarian cancer who had either (i) advanced disease and had previously had TFGT (n=12) or (ii)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Decision Making
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Genetic Testing

Share to Interviews as Topic

Share to Ovarian Neoplasms

Share to Patient Acceptance of Health Care

Share to Precision Medicine

Source

Identifiers

PMID: 22032838
DOI: 10.1016/j.ygyno.2011.09.040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.PMID 22032838Read ↗

Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer.Semantic proximity Read ↗

Patients’ Views of Treatment‐Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 TestingSemantic proximity Read ↗

An exploratory qualitative study of women's perceptions of risk management options for familial ovarian cancer: implications for informed decision making.Semantic proximity Read ↗

Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.Semantic proximity Read ↗

A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes.Semantic proximity Read ↗

Exploring the Emotional Effects of Reproductive Decision-Making in Women With a BRCA Pathogenic Variant.Semantic proximity Read ↗

When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.Semantic proximity Read ↗

Making Sense of a Health Threat: Illness Representations, Coping, and Psychological Distress among BRCA1/2 Mutation Carriers.Semantic proximity Read ↗

Adapting the coping in deliberation (CODE) framework: a multi-method approach in the context of familial ovarian cancer risk management.Semantic proximity Read ↗

How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.Semantic proximity Read ↗

Benefit finding in response to BRCA1/2 testing.Semantic proximity Read ↗

Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.